Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Sb-202190. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 known ✓ | Q16539 | 15/20 | 0.97 |
| ▸ | PRKD3 known ✓ | O94806 | 3/20 | 0.97 |
| ▸ | EGFR known ✓ | P00533 | 1/20 | 0.97 |
| ▸ | NTRK3 known ✓ | Q16288 | 1/20 | 0.97 |
| ▸ | NTRK2 known ✓ | Q16620 | 1/20 | 0.97 |
| ▸ | LCK known ✓ | P06239 | 1/20 | 0.68 |
| ▸ | RET known ✓ | P07949 | 1/20 | 0.68 |
| ▸ | ROCK1 known ✓ | Q13464 | 1/20 | 0.68 |
| ▸ | ERBB4 known ✓ | Q15303 | 1/20 | 0.68 |
| ▸ | MAPK13 | O15264 | 15/20 | 0.97 |
| ▸ | MAPK12 | P53778 | 15/20 | 0.97 |
| ▸ | MAPK11 | Q15759 | 15/20 | 0.97 |
| ▸ | GCGR | P47871 | 13/20 | 0.97 |
| ▸ | ALOX5 | P09917 | 12/20 | 0.97 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.97 |
| ▸ | FRK | P42685 | 3/20 | 0.97 |
| ▸ | MAPK9 | P45984 | 3/20 | 0.97 |
| ▸ | CSNK1A1 | P48729 | 3/20 | 0.97 |
| ▸ | CSNK1D | P48730 | 3/20 | 0.97 |
| ▸ | GSK3B | P49841 | 3/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9195650 | 0.99 | MAPK13 (1.00) | MAPK13MAPK12MAPK11MAPK14GCGR | |
| Sb-202190 SCHEMBL3386753 | 0.99 | MAPK13 (1.00) | MAPK13MAPK12MAPK11MAPK14GCGR | |
| Sb-202190 SCHEMBL158854 | 0.99 | MAPK13 (1.00) | MAPK13MAPK12MAPK11MAPK14GCGR | |
| SCHEMBL19868925 | 0.91 | MAPK11 (1.00) | MAPK13MAPK12MAPK11MAPK14GCGR | |
| SCHEMBL15075603 | 0.91 | MAPK11 (1.00) | MAPK13MAPK12MAPK11MAPK14GCGR | |
| Sb-202190 SCHEMBL6420498 | 0.88 | MAPK13 (0.81) | MAPK13MAPK12MAPK11MAPK14GCGR | |
| SCHEMBL28486758 | 0.86 | MAPK14 (1.00) | MAPK13MAPK12MAPK11MAPK14GCGR | |
| SCHEMBL4552316 | 0.86 | MAPK14 (1.00) | MAPK13MAPK12MAPK11MAPK14GCGR | |
| SCHEMBL6469877 | 0.86 | MAPK14 (1.00) | MAPK13MAPK12MAPK11MAPK14GCGR | |
| SCHEMBL2650702 | 0.86 | MAPK11 (1.00) | MAPK13MAPK12MAPK11MAPK14GCGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119709402-A | Microfluidic chip for dynamic culture of nasal epithelial organoids and culture method thereof | 深圳逸芯生命科学有限公司 | 2025-03-28 | — | — | CN | claimed |
| CN-118995571-A | Human nasal epithelial organoid expansion medium and extraction and culture method of human primary nasal epithelial cells | 广州逸芯生命科学有限公司 | 2024-11-22 | — | — | CN | claimed |
| WO-2024189434-A1 | USE OF NADOLOL TO TREAT PULMONARY SYMPTOMS ASSOCIATED WITH INFECTIONS WITH SARS-CoV-2 | CHRONIC AIRWAY THERAPEUTICS LIMITED (AU) | 2024-09-19 | — | — | WO | claimed |
| CN-116942832-A | Novel anti-infective strategy for combined infection of influenza virus and staphylococcus aureus | 归属疗法有限公司 | 2023-10-27 | — | — | CN | claimed |
| US-20220275062-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OR PREVENTION OF SEVERE INFLUENZA | ORPH PHARMA IP COMPANY LIMITED (GB) | 2022-09-01 | — | — | US | claimed |
| US-20220096590-A1 | NOVEL-ANTI-INFECTIVE STRATEGY AGAINST INFLUENZA VIRUS AND S. AUREUS COINFECTIONS | ATRIVA THERAPEUTICS GMBH (DE) | 2022-03-31 | — | — | US | claimed |
| EP-4648772-A1 | MEDICINAL PRODUCTS AND METHODS FOR THE ALLEVIATION OF CANCER IMMUNOTHERAPY-ASSOCIATED CYTOKINE RELEASE SYNDROME | Poolbeg Pharma (UK) Limited (GB) | 2025-11-19 | — | — | EP | disclosed |
| US-20250302883-A1 | NORMALIZATION OF CULTURE OF CORNEAL ENDOTHELIAL CELLS | KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION (JP) | 2025-10-02 | — | — | US | disclosed |
| WO-2025130396-A1 | TRMT61A INHIBITOR PGG IN THE TREATMENT OF COLORECTAL CANCER | THE CHINESE UNIVERSITY OF HONG KONG (CN) | 2025-06-26 | — | — | WO | disclosed |
| WO-2025090966-A1 | MEK INHIBITORS, ALONE OR IN COMBINATION WITH CDK4/5 INHIBITORS, FOR USE IN TREATING CANCER | VEVO THERAPEUTICS, INC. (US) | 2025-05-01 | — | — | WO | disclosed |
| WO-2025084780-A1 | CELL LINE-BASED CANCER ORGANOID AND METHOD FOR EVALUATING DRUG TOXICITY USING SAME | ㈜바이오솔빅스 | 2025-04-24 | — | — | WO | disclosed |
| CN-119709402-A | Microfluidic chip for dynamic culture of nasal epithelial organoids and culture method thereof | 深圳逸芯生命科学有限公司 | 2025-03-28 | — | — | CN | disclosed |
| US-20250011400-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OR PREVENTION OF SEVERE INFLUENZA | Poolbeg Pharma (UK) Limited (GB) | 2025-01-09 | — | — | US | disclosed |
| US-11339207-B2 | Methods and compounds for the treatment or prevention of severe influenza | ORPH PHARMA IP COMPANY LIMITED (GB) | 2022-05-24 | — | — | US | disclosed |
| US-20220133704-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | FULCRUM THERAPEUTICS INC (US) | 2022-05-05 | — | — | US | disclosed |
| CN-111601593-B | P38 kinase inhibitor reduces DUX4 and downstream gene expression for treatment of FSHD | 弗尔康医疗公司 | 2022-04-15 | — | — | CN | disclosed |
| US-11291659-B2 | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD | Fulcrum Therapeutics, Inc. (US) | 2022-04-05 | — | — | US | disclosed |
| US-20220096590-A1 | NOVEL-ANTI-INFECTIVE STRATEGY AGAINST INFLUENZA VIRUS AND S. AUREUS COINFECTIONS | ATRIVA THERAPEUTICS GMBH (DE) | 2022-03-31 | — | — | US | disclosed |
| EP-3957722-A1 | PRODUCTION METHOD AND KIT OF INDUCED PLURIPOTENT STEM CELLS | Keio University (JP) | 2022-02-23 | — | — | EP | disclosed |
| US-20080119498-A1 | Therapeutic Agent for Pruritus Comprising P38 Map Kinase Inhibitor as the Active Ingredient | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250011400-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OR PREVENTION OF SEVERE INFLUENZA | CXCL10, MAPK10, MAPK1 | MAPK14 15/4885PRKD3 813/4885EGFR 872/4885 |
| US-20220133704-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | ZFX, TBL1XR1, TRIM28 | MAPK14 191/4885PRKD3 154/4885EGFR 4692/4885 |
| US-20220096590-A1 | NOVEL-ANTI-INFECTIVE STRATEGY AGAINST INFLUENZA VIRUS AND S. AUREUS COINFECTIONS | MAPK1, MAP2K1, MAP2K6 | MAPK14 14/4885PRKD3 766/4885EGFR 749/4885 |
| US-20220275062-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OR PREVENTION OF SEVERE INFLUENZA | CXCL10, MAPK10, CCL11 | MAPK14 14/4885PRKD3 728/4885EGFR 861/4885 |
| US-11291659-B2 | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD | ZFX, TBL1XR1, TRIM28 | MAPK14 191/4885PRKD3 154/4885EGFR 4692/4885 |
| US-11339207-B2 | Methods and compounds for the treatment or prevention of severe influenza | CXCL10, MAPK10, MAPK1 | MAPK14 15/4885PRKD3 813/4885EGFR 872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.